GlassScriptPhysician profile
Kimberly Reilly
NPI 1720792708
$2,837.02
in general payments reported to CMS, 2019-2025
23 companies · $63.37 in 2025
The $63.37 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,271 · 2024: $503 · 2025: $63.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,739 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.03 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.23 | 2023-2025 | |
| Horizon Therapeutics Plc | $241.80 | 2023 | Uplizna |
| Genentech USA, INC. | $234.08 | 2023-2024 | Ocrevus |
| Biogen, INC. | $232.64 | 2023-2024 | Vumerity, Tysabri, Avonex |
| Pfizer INC. | $170.79 | 2023-2024 | |
| Eisai INC. | $164.52 | 2023-2024 | |
| Lilly USA, LLC | $156.25 | 2023 | Emgality, Amyvid |
| Lundbeck LLC | $127.54 | 2023-2024 | Vyepti |
| Impel Pharmaceuticals INC. | $119.23 | 2023 | Trudhesa |
| Emd Serono, INC. | $113.13 | 2023-2024 | Mavenclad |
| Celgene Corporation | $108.37 | 2023 | Zeposia |
| Genzyme Corporation | $97.99 | 2023 | |
| Ucb, INC. | $83.13 | 2023-2024 | Rystiggo |
| Teva Pharmaceuticals USA, INC. | $80.20 | 2023 | Ajovy |
| Banner Life Sciences, LLC | $61.87 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $59.86 | 2024 | Uplizna |
| Ani Pharmaceuticals, INC. | $56.76 | 2023 | Purified Cortrophin Gel |
| Microtransponder, INC. | $31.85 | 2023 | |
| Axsome Therapeutics, INC. | $31.80 | 2023 | Sunosi |
| Alexion Pharmaceuticals, INC. | $26.85 | 2023 | Ultomiris |
| Jazz Pharmaceuticals INC. | $25.10 | 2023 | Epidiolex |
| Upsher-Smith Laboratories LLC | $23.39 | 2023 | |
| Life Molecular Imaging LTD | $16.64 | 2023 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Reilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.